208 related articles for article (PubMed ID: 37197025)
1. Encapsulated Oxovanadium(IV) and Dioxovanadium(V) Complexes into Solid Lipid Nanoparticles Increase Cytotoxicity Against MDA-MB-231 Cell Line.
Kostrzewa T; Nowak I; Feliczak-Guzik A; Drzeżdżon J; Jacewicz D; Górska-Ponikowska M; Kuban-Jankowska A
Int J Nanomedicine; 2023; 18():2507-2523. PubMed ID: 37197025
[TBL] [Abstract][Full Text] [Related]
2. Development of Curcumin-Loaded Solid Lipid Nanoparticles Utilizing Glyceryl Monostearate as Single Lipid Using QbD Approach: Characterization and Evaluation of Anticancer Activity Against Human Breast Cancer Cell Line.
Bhatt H; Rompicharla SVK; Komanduri N; Aashma S; Paradkar S; Ghosh B; Biswas S
Curr Drug Deliv; 2018; 15(9):1271-1283. PubMed ID: 29732970
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, In Vitro, and Computational Studies of PTP1B Phosphatase Inhibitors Based on Oxovanadium(IV) and Dioxovanadium(V) Complexes.
Kostrzewa T; Jończyk J; Drzeżdżon J; Jacewicz D; Górska-Ponikowska M; Kołaczkowski M; Kuban-Jankowska A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806035
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and
Darabi F; Saidijam M; Nouri F; Mahjub R; Soleimani M
Biomed Res Int; 2022; 2022():6253978. PubMed ID: 35845934
[TBL] [Abstract][Full Text] [Related]
5. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
6. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
Das S; Ng WK; Tan RB
Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358
[TBL] [Abstract][Full Text] [Related]
7. Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics.
Ji P; Yu T; Liu Y; Jiang J; Xu J; Zhao Y; Hao Y; Qiu Y; Zhao W; Wu C
Drug Des Devel Ther; 2016; 10():911-25. PubMed ID: 27041995
[TBL] [Abstract][Full Text] [Related]
8. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies.
Wang S; Chen T; Chen R; Hu Y; Chen M; Wang Y
Int J Pharm; 2012 Jul; 430(1-2):238-46. PubMed ID: 22465546
[TBL] [Abstract][Full Text] [Related]
9. Solid lipid nanoparticles for thermoresponsive targeting: evidence from spectrophotometry, electrochemical, and cytotoxicity studies.
Rehman M; Ihsan A; Madni A; Bajwa SZ; Shi D; Webster TJ; Khan WS
Int J Nanomedicine; 2017; 12():8325-8336. PubMed ID: 29200845
[TBL] [Abstract][Full Text] [Related]
10. Impact Of Penetratin Stereochemistry On The Oral Bioavailability Of Insulin-Loaded Solid Lipid Nanoparticles.
Alsulays BB; Anwer MK; Soliman GA; Alshehri SM; Khafagy ES
Int J Nanomedicine; 2019; 14():9127-9138. PubMed ID: 31819423
[TBL] [Abstract][Full Text] [Related]
11. Skin Delivery and in Vitro Biological Evaluation of Trans-Resveratrol-Loaded Solid Lipid Nanoparticles for Skin Disorder Therapies.
Rigon RB; Fachinetti N; Severino P; Santana MH; Chorilli M
Molecules; 2016 Jan; 21(1):E116. PubMed ID: 26805794
[TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of solid lipid nanoparticles loaded with frankincense and myrrh oil.
Shi F; Zhao JH; Liu Y; Wang Z; Zhang YT; Feng NP
Int J Nanomedicine; 2012; 7():2033-43. PubMed ID: 22619540
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of Brigatinib loaded solid lipid nanoparticles: In-vitro cytotoxicity against human carcinoma A549 lung cell lines.
Ahmed MM; Fatima F; Anwer MK; Aldawsari MF; Alsaidan YSM; Alfaiz SA; Haque A; Az A; Alhazzani K
Chem Phys Lipids; 2020 Nov; 233():105003. PubMed ID: 33096096
[TBL] [Abstract][Full Text] [Related]
14. Characterization and stability of nanostructured lipid carriers as drug delivery system.
Abbasalipourkabir R; Salehzadeh A; Abdullah R
Pak J Biol Sci; 2012 Feb; 15(3):141-6. PubMed ID: 22866544
[TBL] [Abstract][Full Text] [Related]
15. Effect of liquid-to-solid lipid ratio on characterizations of flurbiprofen-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) for transdermal administration.
Song A; Zhang X; Li Y; Mao X; Han F
Drug Dev Ind Pharm; 2016 Aug; 42(8):1308-14. PubMed ID: 26707734
[TBL] [Abstract][Full Text] [Related]
16. Enhancement in antifungal activity of eugenol in immunosuppressed rats through lipid nanocarriers.
Garg A; Singh S
Colloids Surf B Biointerfaces; 2011 Oct; 87(2):280-8. PubMed ID: 21689909
[TBL] [Abstract][Full Text] [Related]
17. Mannosylated Solid Lipid Nanocarriers of Chrysin to Target Gastric Cancer: Optimization and Cell Line Study.
Pandey SS; Shaikh FI; Gupta AR; Vaidya RJ
Curr Drug Deliv; 2021; 18(10):1574-1584. PubMed ID: 33745434
[TBL] [Abstract][Full Text] [Related]
18. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery.
Wu M; Fan Y; Lv S; Xiao B; Ye M; Zhu X
Drug Deliv; 2016 Oct; 23(8):2720-2725. PubMed ID: 26203691
[TBL] [Abstract][Full Text] [Related]
19. Relationship between Antioxidant Activity and Ligand Basicity in the Dipicolinate Series of Oxovanadium(IV) and Dioxovanadium(V) Complexes.
Drzeżdżon J; Pawlak M; Matyka N; Sikorski A; Gawdzik B; Jacewicz D
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576048
[TBL] [Abstract][Full Text] [Related]
20. Loading
Dousti M; Sari S; Saffari M; Kelidari H; Asare-Addo K; Nokhodchi A
Pharm Dev Technol; 2022 Jan; 27(1):63-71. PubMed ID: 34939892
[No Abstract] [Full Text] [Related]
[Next] [New Search]
